Skip to main content Back to Top
Advertisement

5/20/2019

Methyldopa Tablets

Products Affected - Description

    • Methyldopa oral tablet, Mylan, 250 mg, bottle, 100 count, NDC 00378-0611-01
    • Methyldopa oral tablet, Mylan, 500 mg, bottle, 100 count, NDC 00378-0421-01
    • Methyldopate hydrochloride injection, American Regent, 50 mg/mL, 5 mL single dose vial, 10 count, NDC 00517-8905-10

Reason for the Shortage

    • Accord has methyldopa tablets available.
    • Mylan did not provide a reason for the shortage.
    • Teva discontinued methyldopa tablets in 2018.

Available Products

    • Methyldopa oral tablet, Accord, 250 mg, bottle, 100 count, NDC 16729-0030-01
    • Methyldopa oral tablet, Accord, 250 mg, bottle, 500 count, NDC 16729-0030-16
    • Methyldopa oral tablet, Accord, 500 mg, bottle, 100 count, NDC 16729-0031-01
    • Methyldopa oral tablet, Accord, 500 mg, bottle, 500 count, NDC 16729-0031-16

Estimated Resupply Dates

    • Mylan has methyldopa 250 mg tablets and 500 mg tablets in 100 count bottles on back order and the company estimates a release date of early-January 2020. The 250 mg tablets and 500 mg tablets in 100 count unit-dose packs are on back order and the company estimates a release date of mid-January 2020.

Updated

Updated May 20, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created August 28, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins